DNA methylation of DKK3 modulates docetaxel chemoresistance in human nonsmall cell lung cancer cell

Cancer Biotherapy & Radiopharmaceuticals
Leilei TaoLong-Bang Chen

Abstract

Dickkopf-related protein 3 (DKK3) gene, as a tumor suppressor gene, has been discovered in various cancers, but its relationship with tumor chemoresistance is still unclear. In this study, this laboratory detected that DNA methylation contributes to the downregulation of DKK3 in docetaxel resistance of human lung cancer cells and its possible biochemical mechanism. DKK3 has been proved to be downregulated by hypermethylation in docetaxel-resistant lung cancer cells. Upregulation of DKK3 can reverse the chemoresistance of docetaxel-resistant cell lines in vitro by growth inhibition and enhancement of apoptosis. Conversely, downregulation of DKK3 could induce parental human lung cancer cells insensitivity to docetaxel by promoting proliferative capacity and inhibiting apoptosis of cancer cells. In addition, the authors observed that overexpression of DKK3 might decrease the expression of P-glycoprotein. All results suggested that epigenetic downregulation of DKK3 leads to docetaxel resistance in human nonsmall cell lung cancer (NSCLC) cells by increased expression of P-glycoprotein. DKK3 may reveal a novel molecular target for docetaxel resistance for NSCLC patients in the future.

References

Sep 16, 2009·Carcinogenesis·Shikhar SharmaPeter A Jones
Nov 11, 2009·Journal of Cellular and Molecular Medicine·Wang RuiChen Long-Bang
Mar 2, 2010·Cytoskeleton·Luis J Leandro-GarcíaCristina Rodríguez-Antona
Jul 30, 2010·The Journal of Obstetrics and Gynaecology Research·Tao JiangShulan Zhang
Oct 5, 2010·Nature Reviews. Drug Discovery·Charles Dumontet, Mary Ann Jordan
Jan 27, 2011·Molecular Carcinogenesis·Koji UenoRajvir Dahiya
Nov 11, 2011·Journal of Translational Medicine·Christoph ZenzmaierPeter Berger
Jul 19, 2012·IUBMB Life·Hyun-Jung ChoiYoung-Guen Kwon
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
May 3, 2013·Molecular Cancer Therapeutics·Sucharita J Mistry, William K Oh
Jun 7, 2013·Drug Metabolism and Drug Interactions·Nicolás González-VacarezzaAdrián Llerena
Jul 19, 2013·Molecular Cancer Therapeutics·Yezi ZhuAllen C Gao
Jul 28, 2013·Biochemical Pharmacology·Isabel Marzo, Javier Naval
Sep 4, 2013·Nature Reviews. Clinical Oncology·Elizabeth A KuczynskiRobert S Kerbel
Jan 28, 2014·Anti-cancer Drugs·Monika JoshiChandra P Belani
Mar 29, 2014·Molecular Medicine Reports·Chang-Cheng GuoJun-Hua Zheng

❮ Previous
Next ❯

Citations

Apr 21, 2016·Toxicology and Applied Pharmacology·Timothy N PerkinsNiki L Reynaert
Jun 18, 2019·Artificial Cells, Nanomedicine, and Biotechnology·Keqian ZhangZhe Wang
Dec 10, 2016·Frontiers in Oncology·Tom G KeulersKasper M A Rouschop
Aug 28, 2020·Frontiers in Oncology·Susana Romero-GarciaAngeles Carlos-Reyes

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
transfection
xenografts

Software Mentioned

SPSS16

Related Concepts

Related Feeds

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.